Top

Published in:

Open Access 01-02-2015 | Epidemiology

Utility of ¹⁸F FDG-PET/CT for predicting prognosis of luminal-type breast cancer

Authors: Kenjiro Aogi, Takayuki Kadoya, Yoshifumi Sugawara, Sachiko Kiyoto, Hideo Shigematsu, Norio Masumoto, Morihito Okada

Published in: Breast Cancer Research and Treatment | Issue 1/2015

Abstract

Postoperative prognosis is better for hormonal receptor-positive breast cancer than for other phenotypes; however, there are no definitive predictive factors for relapse or survival. This study aimed to evaluate the maximum standardized uptake value (SUVmax) on ¹⁸F-fluoro-2-deoxy-glucose positron emission tomography/computed tomography (FDG-PET/CT) and clinicopathological characteristics as possible predictors of postoperative relapse-free survival (RFS) and overall survival (OS) in hormonal receptor-positive breast cancer patients. We evaluated 262 patients with Stage I–III breast cancer diagnosed as luminal type (luminal A, 166; luminal B, 96 patients) who underwent preoperative FDG-PET/CT between January 2006 and December 2011 at two institutions. The relationships among SUVmax and clinicopathological factors (age, clinical T/N stage, nuclear grade, lymph node metastasis and vascular invasion) were evaluated. A phantom study was performed to correct differences in PET/CT analysis between two institutions. The patients were divided according to the SUVmax cutoff on receiver operating characteristic (ROC) analysis for OS (≤6.0 group vs. >6.0 group, AUC = 0.742). Clinical T-factor and nuclear grade were significantly correlated with SUVmax (p < 0.0001 and p = 0.0092, respectively). In the uni- and multivariate analyses using the Cox model for relapse, SUVmax was significant (p = 0.013 and p = 0.055, respectively) among characteristics. RFS curves showed that prognosis was significantly better for the SUVmax ≤ 6.0 group than for the SUVmax > 6.0 group (p = 0.004). Similarly, SUVmax was significant for OS (p = 0.007 and p = 0.008). OS was significantly different between the SUVmax ≤ 6.0 and >6.0 groups (p < 0.001). SUVmax was useful for predicting outcomes in patients with luminal-type breast cancer.

Vansteenkiste JF, Stroobants SG, Dupont PJ, De Leyn PR, Verbeken EK, Deneffe GJ et al (1999) Prognostic importance of the standardized uptake value on (18)F-fluoro-2-deoxy-glucose-positron emission tomography scan in non-small-cell lung cancer: an analysis of 125 cases. Leuven Lung Cancer Group. J Clin Oncol 17:3201–3206PubMed

Okazumi S, Isono K, Enomoto K, Kikuchi T, Ozaki M, Yamamoto H et al (1992) Evaluation of liver tumors using fluorine—18-fluoro-2-deoxy-d-glucose PET. J Nucl Med 33:339–344

Fuster D, Duch J, Paredes P, Velasco M, Muñoz M, Santamaría G et al (2008) Preoperative staging of large primary breast cancer with [18F]fluorodeoxyglucose positron emission tomography/computed tomography compared with conventional imaging procedures. J Clin Oncol 26:4746–4751CrossRefPubMed

Groheux D, Hindié E, Delord M, Giacchetti S, Hamy AS, de Bazelaire C et al (2012) Prognostic impact of (18)FDG-PET-CT findings in clinical stage III and IIB breast cancer. J Natl Cancer Inst 104:1879–1887CrossRefPubMedCentralPubMed

Okada J, Yoshikawa K, Itami M, Imaseki K, Uno K, Itami J et al (1992) Positron emission tomography using fluorine-18-fluorodeoxyglucose in malignant lymphoma: a comparison with proliferative activity. J Nucl Med 33:325–329PubMed

Groheux D, Hindié E, Giacchetti S, Hamy AS, Berger F, Merlet P et al (2014) Early assessment with 18F-fluorodeoxyglucose positron emission tomography/computed tomography can help predict the outcome of neoadjuvant chemotherapy in triple negative breast cancer. Eur J Cancer 50:1864–1871CrossRefPubMed

Berriolo-Riedinger A, Touzery C, Riedinger JM, Toubeau M, Coudert B, Arnould L et al (2007) [18F]FDG-PET predicts complete pathological response of breast cancer to neoadjuvant chemotherapy. Eur J Nucl Med Mol Imaging 34:1915–1924CrossRefPubMed

Humbert O, Berriolo-Riedinger A, Riedinger JM, Coudert B, Arnould L, Cochet A et al (2012) Changes in 18F-FDG tumor metabolism after a first course of neoadjuvant chemotherapy in breast cancer: influence of tumor subtypes. Ann Oncol 23:2572–2577CrossRefPubMed

Buck A, Schirrmeister H, Kuhn T, Shen C, Kalker T, Kotzerke J et al (2002) FDG uptake in breast cancer: correlation with biological and clinical prognostic parameters. Eur J Nucl Med Mol Imaging 29:1317–1323CrossRefPubMed

10.

Smith TA, Sharma RI, Thompson AM, Paulin FE (2006) Tumor 18F-FDG incorporation is enhanced by attenuation of P53 function in breast cancer cells in vitro. J Nucl Med 47:1525–1530PubMed

11.

Dehdashti F, Mortimer JE, Siegel BA, Griffeth LK, Bonasera TJ, Fusselman MJ et al (1995) Positron tomographic assessment of estrogen receptors in breast cancer: comparison with FDG-PET and in vitro receptor assays. J Nucl Med 36:1766–1774PubMed

12.

Crippa F, Seregni E, Agresti R, Chiesa C, Pascali C, Bogni A et al (1998) Association between [18F]fluorodeoxyglucose uptake and postoperative histopathology, hormone receptor status, thymidine labelling index and p53 in primary breast cancer: a preliminary observation. Eur J Nucl Med 25:1429–1434CrossRefPubMed

13.

Avril N, Menzel M, Dose J, Schelling M, Weber W, Jänicke F et al (2001) Glucose metabolism of breast cancer assessed by 18F-FDG PET: histologic and immunohistochemical tissue analysis. J Nucl Med 42:9–16PubMed

14.

Bos R, van Der Hoeven JJ, van Der Wall E, van Der Groep P, van Diest PJ, Comans EF et al (2002) Biologic correlates of (18)fluorodeoxyglucose uptake in human breast cancer measured by positron emission tomography. J Clin Oncol 20:379–387CrossRefPubMed

15.

Kumar R, Chauhan A, Zhuang H, Chandra P, Schnall M, Alavi A (2006) Clinicopathologic factors associated with false negative FDG-PET in primary breast cancer. Breast Cancer Res Treat 98:267–274CrossRefPubMed

16.

Groheux D, Giacchetti S, Moretti JL, Porcher R, Espié M, Lehmann-Che J et al (2011) Correlation of high 18F-FDG uptake to clinical, pathological and biological prognostic factors in breast cancer. Eur J Nucl Med Mol Imaging 38:426–435CrossRefPubMed

17.

Fasanella S, Leonardi E, Cantaloni C, Eccher C, Bazzanella I, Aldovini D et al (2011) Proliferative activity in human breast cancer: Ki-67 automated evaluation and the influence of different Ki-67 equivalent antibodies. Diagn Pathol 6:S7CrossRefPubMedCentralPubMed

18.

Tchou J, Sonnad SS, Bergey MR, Basu S, Tomaszewski J, Alavi A et al (2010) Degree of tumor FDG uptake correlates with proliferation index in triple negative breast cancer. Mol Imaging Biol 12:657–662CrossRefPubMed

19.

Oshida M, Uno K, Suzuki M, Nagashima T, Hashimoto H, Yagata H et al (1998) Predicting the prognoses of breast carcinoma patients with positron emission tomography using 2-deoxy-2-fluoro[18F]-D-glucose. Cancer 82:2227–2234CrossRefPubMed

20.

Na F, Wang J, Li C, Deng L, Xue J, Lu Y (2014) Primary tumor standardized uptake value measured on F18-Fluorodeoxyglucose positron emission tomography is of prediction value for survival and local control in non-small-cell lung cancer receiving radiotherapy: meta-analysis. J Thorac Oncol 9:834–842CrossRefPubMedCentralPubMed

21.

Berghmans T, Dusart M, Paesmans M, Hossein-Foucher C, Buvat I, Castaigne C et al (2008) Primary tumor standardized uptake value (SUVmax) measured on fluorodeoxyglucose positron emission tomography (FDG-PET) is of prognostic value for survival in non-small cell lung cancer (NSCLC): a systematic review and meta-analysis (MA) by the European Lung Cancer Working Party for the IASLC Lung Cancer Staging Project. J Thorac Oncol 3:6–12CrossRefPubMed

22.

Kadoya T, Aogi K, Kiyoto S, Masumoto N, Sugawara Y, Okada M (2013) Role of maximum standardized uptake value in fluorodeoxyglucose positron emission tomography/computed tomography predicts malignancy grade and prognosis of operable breast cancer: a multi-institute study. Breast Cancer Res Treat 141:269–275CrossRefPubMedCentralPubMed

23.

Perou CM, Sorlie T, Eisen MB, van de Rijn M, Jeffrey SS, Rees CA et al (2000) Molecular portraits of human breast tumours. Nature 406:747–752CrossRefPubMed

24.

Sørlie T, Perou CM, Tibshirani R, Aas T, Geisler S, Johnsen H et al (2001) Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci USA 98:10869–10874CrossRefPubMedCentralPubMed

25.

The Japanese Breast Cancer Society (2008) General rules for clinical and pathological recording of breast cancer, 16th edn. Kanehara, Tokyo

26.

Nakayama H, Okumura S, Daisaki H, Kato Y, Uehara H, Adachi S et al (2010) Value of integrated positron emission tomography revised using a phantom study to evaluate malignancy grade of lung adenocarcinoma: a multicenter study. Cancer 116:3170–3177CrossRefPubMed

27.

Goldhirsch A, Wood WC, Coates AS, Gelber RD, Thürlimann B, Senn HJ et al (2011) Strategies for subtypes–dealing with the diversity of breast cancer: highlights of the St. Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2011. Ann Oncol 22:1736–1747CrossRefPubMedCentralPubMed

28.

Cheang MC, Chia SK, Voduc D, Gao D, Leung S, Snider J et al (2009) Ki67 index, HER2 status, and prognosis of patients with luminal B breast cancer. J Natl Cancer Inst 101:736–750CrossRefPubMedCentralPubMed

29.

Courdi A, Largillier R, Ferrero JM, Lallement M, Raoust I, Ettore F et al (2006) Early versus late local recurrences after conservative treatment of breast carcinoma: differences in primary tumor characteristics and patient outcome. Oncology 71:361–368CrossRefPubMed

30.

Sestak I, Dowsett M, Zabaglo L, Lopez-Knowles E, Ferree S, Cowens JW et al (2013) Factors predicting late recurrence for estrogen receptor-positive breast cancer. J Natl Cancer Inst 105(19):1504–1511CrossRefPubMedCentralPubMed

31.

Saphner T, Tormey DC, Gray R (1996) Annual hazard rates of recurrence for breast cancer after primary therapy. J Clin Oncol 14(10):2738–2746PubMed

32.

Ahn SG, Lee HM, Cho SH, Bae SJ, Lee SA, Hwang SH et al (2013) The difference in prognostic factors between early recurrence and late recurrence in estrogen receptor-positive breast cancer: nodal stage differently impacts early and late recurrence. PLoS One 8(5):e63510CrossRefPubMedCentralPubMed

33.

Basu S, Chen W, Tchou J, Mavi A, Cermik T, Czerniecki B et al (2008) Comparison of triple-negative and estrogen receptor-positive/progesterone receptor-positive/HER2-negative breast carcinoma using quantitative fluorine-18 fluorodeoxyglucose/positron emission tomography imaging parameters: a potentially useful method for disease characterization. Cancer 112(5):995–1000CrossRefPubMed

34.

Ohara M, Shigematsu M, Tsutani Y, Emi A, Masumoto N, Ozaki S et al (2013) Role of FDG-PET/CT in evaluating surgical outcomes of operable breast cancer–usefulness for malignant grade of triple-negative breast cancer. Breast 22(5):958–963CrossRefPubMed

35.

Cintolo JA, Tchou J, Pryma DA (2013) Diagnostic and prognostic application of positron emission tomography in breast imaging: emerging uses and the role of PET in monitoring treatment response. Breast Cancer Res Treat 138(2):331–346CrossRefPubMed

Title: Utility of 18F FDG-PET/CT for predicting prognosis of luminal-type breast cancer
Authors: Kenjiro Aogi
Takayuki Kadoya
Yoshifumi Sugawara
Sachiko Kiyoto
Hideo Shigematsu
Norio Masumoto
Morihito Okada
Publication date: 01-02-2015
Publisher: Springer US
Published in: Breast Cancer Research and Treatment / Issue 1/2015
Print ISSN: 0167-6806
Electronic ISSN: 1573-7217
DOI: https://doi.org/10.1007/s10549-015-3303-9

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 1/2015

DNA damage response markers are differentially expressed in BRCA-mutated breast cancers

Tyrosine kinase discoidin domain receptors DDR1 and DDR2 are coordinately deregulated in triple-negative breast cancer

Mammographic breast density and breast cancer risk: interactions of percent density, absolute dense, and non-dense areas with breast cancer risk factors

Autocrine control of MIP-2 secretion from metastatic breast cancer cells is mediated by CXCR2: a mechanism for possible resistance to CXCR2 antagonists

Prognostic significance of epithelial–mesenchymal transition proteins Twist and Foxc2 in phyllodes tumours of the breast

Rationale for targeting fibroblast growth factor receptor signaling in breast cancer

Keynote webinar | Spotlight on antibody–drug conjugates in cancer